needed effects
cobicistat
elvitegravir
emtricitabine
tenofovir
unwanted side effects
medical attention
following side effects
taking cobicistat
elvitegravir
emtricitabine
tenofovir
check
doctor
cobicistat
elvitegravir
emtricitabine
tenofovir side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
clinical trials
common side effects
cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
nausea
diarrhea
headache
safety profiles in patients with mild
moderate renal dysfunction
patients
hiv
hepatitis b virus
safety profiles in patients with normal renal function
patients with hiv
monoinfection
common side effects
clinical trials with cobicistat
elvitegravir
emtricitabine
tenofovir disoproxil fumarate
df
nausea
diarrhea
upper respiratory tract infection
depression in therapy-naive patients
nausea
fatigue in virologically-suppressed patients
manufacturer product information for cobicistat
elvitegravir
emtricitabine
tenofovir df
cobicistat
emtricitabine
tenofovir alafenamide
hematuriacobicistat
elvitegravir
emtricitabine
tenofovir df
proteinuria
hematuriaemtricitabine
tenofovir df
frequency
glycosuriatenofovir df
postmarketing reports
proteinuria
polyuria
hematuria
rbc/high power field
patients
using cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
cobicistat
elvitegravir
emtricitabine
tenofovir df
proteinuria
grades
patients
using cobicistat
elvitegravir
emtricitabine
tenofovir df
glycosuria
emtricitabine
tenofovir df
cobicistat
emtricitabine
tenofovir alafenamide
nausea-common
diarrhea
vomiting
abdominal pain
dyspepsiacobicistat
elvitegravir
emtricitabine
tenofovir df
elevated lipase
nausea
diarrhea
flatulence
elevated amylase
abdominal pain
dyspepsia
constipationemtricitabine
tenofovir df
dyspepsia
vomitingtenofovir df
elevated amylase
including
elevated pancreatic amylase
elevated serum lipase
abdominal distension-uncommon
pancreatitis-postmarketing reports
abdominal pain
elevated amylase
times
upper limit of normal
uln
patients
using cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
cobicistat
elvitegravir
emtricitabine
tenofovir df
serum amylase
x uln in those
using cobicistat
elvitegravir
emtricitabine
tenofovir df
lipase
elevated lipase
grades
patients
using cobicistat
elvitegravir
emtricitabine
tenofovir df
dyspepsia
vomiting
patients
receiving emtricitabine
tenofovir df with other antiretroviral drugs in other clinical trials
elevated amylase
including
elevated pancreatic amylase
elevated serum lipase
abdominal distension
pancreatitis
clinical trials
postmarketing experience for tenofovir df with other antiretrovirals
pancreatitis
amylase
postmarketing experience with tenofovir df
clinical trials
significant decline in bmd
therapy-naive hiv
infected patients
using cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
comparison studies
bmd decreases
cobicistat
elvitegravir
emtricitabine
tenofovir df
virologically-suppressed tenofovir
df-treated patients
cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
initial regimen
bmd
baseline
week in those
initial regimen
bmd
patients
cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
elevated creatine kinase
uln
patients
using cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
cobicistat
elvitegravir
emtricitabine
tenofovir df
arthralgia
myalgia
pain
patients
receiving emtricitabine
tenofovir df with other antiretroviral drugs in other clinical trials
elevated creatine kinase
rhabdomyolysis
muscular weakness
osteomalacia
bone pain
contributing
fractures
myopathy
clinical trials
postmarketing experience for tenofovir df with other antiretrovirals
rhabdomyolysis
osteomalacia
bone pain
fractures
muscular weakness
myopathy
postmarketing experience with tenofovir df
rhabdomyolysis
osteomalacia
muscular weakness
myopathy
result of proximal renal tubulopathy
cobicistat
emtricitabine
tenofovir alafenamide
decreased bone mineral density
bmd
elevated creatine kinase-uncommon
fractures
excluding fingers
toes
frequency
increased biochemical markers of bone metabolism
bmdcobicistat
elvitegravir
emtricitabine
tenofovir df
elevated creatine kinase
bone fractures
arthralgia-frequency
decreased bmd
painemtricitabine
tenofovir df
arthralgia
myalgia
paintenofovir df
elevated creatine kinase-uncommon
rhabdomyolysis
osteomalacia
bone pain
contributing
fractures
myopathy-frequency
decreased bmd
biochemical markers of bone metabolismcombination
antiretroviral therapy
frequency
osteonecrosis
cobicistat
emtricitabine
tenofovir alafenamide
headache
dizzinesscobicistat
elvitegravir
emtricitabine
tenofovir df
headache
somnolenceemtricitabine
tenofovir df
paresthesia
peripheral neuropathy
including
peripheral neuritis
neuropathy
paresthesia
peripheral neuropathy
including
peripheral neuritis
neuropathy
patients
receiving emtricitabine
tenofovir df with other antiretroviral drugs in other clinical trials
trials in therapy-naive patients
baseline for the fasting lipid parameters
total cholesterol
direct ldl cholesterol
hdl cholesterol
cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
cobicistat
elvitegravir
emtricitabine
tenofovir df at weeks of therapy
such increases
cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
elevated fasting ldl cholesterol
mg/dl
elevated fasting
total cholesterol
mg/dl
patients
using cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
patients
using cobicistat
elvitegravir
emtricitabine
tenofovir df
clinical trials
following mean increases in fasting lipid values
weeks of therapy
total cholesterol
mg/dl
ldl cholesterol by mg/dl
hdl cholesterol by mg/dl
triglycerides by mg/dl with cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
total cholesterol
mg/dl
ldl cholesterol by mg/dl
hdl cholesterol by mg/dl
triglycerides by mg/dl with cobicistat
elvitegravir
emtricitabine
tenofovir df
elevated alkaline phosphatase
units/l
altered serum glucose
mg/dl
mg/dl
elevated fasting cholesterol
mg/dl
elevated fasting triglycerides
mg/dl
patients
receiving emtricitabine
tenofovir df with other antiretroviral drugs in other clinical trials
hypophosphatemia
hyperglycemia
hypertriglyceridemia
hypokalemia
lactic acidosis
clinical trials
postmarketing experience for tenofovir df with other antiretrovirals
lactic acidosis
hypokalemia
hypophosphatemia
postmarketing experience with tenofovir df
lactic acidosis
steatosis
including
fatal cases
use of nucleoside analogs
hypokalemia
hypophosphatemia
result of proximal renal tubulopathy
cobicistat
emtricitabine
tenofovir alafenamide
increased fasting
increased fasting low-density lipoprotein
ldl
cholesterol
fasting
total cholesterol-frequency
increased high-density lipoprotein
hdl
cholesterol
triglyceridescobicistat
elvitegravir
emtricitabine
tenofovir df
decreased appetite
fasting ldl cholesterol-uncommon
elevated fasting total cholesterol
elevated fasting triglycerides
hdl cholesterolemtricitabine
tenofovir df
frequency
elevated alkaline phosphatase
altered serum glucose
elevated fasting cholesterol
elevated fasting triglyceridestenofovir df
hypophosphatemia-common
hyperglycemia
hypertriglyceridemia-uncommon
hypokalemia-rare
lactic acidosisantiretroviral therapy
frequency
redistribution/accumulation of body fat
including
central obesity
dorsocervical fat enlargement
peripheral wasting
facial wasting
breast enlargement
cushingoid appearance
increased blood lipid levels
glucose levels
cobicistat
emtricitabine
tenofovir alafenamide
fatiguecobicistat
emtricitabine
tenofovir df
fatigueemtricitabine
tenofovir df
abdominal pain
fever
paintenofovir df
asthenia-frequency
vitamin d levelsantiretroviral therapy
frequency
increased weight
abdominal pain
fever
pain
patients
receiving emtricitabine
tenofovir df with other antiretroviral drugs in other clinical trials
asthenia
pain
clinical trials
postmarketing experience for tenofovir df with other antiretrovirals
asthenia
postmarketing experience with tenofovir df
suicidal ideation
suicide attempt
cobicistat
elvitegravir
emtricitabine
tenofovir df in patients with history of depression
psychiatric illness
depression
clinical trials for elvitegravir with other antiretrovirals
depression
anxiety
patients
receiving emtricitabine
tenofovir df with other antiretroviral drugs in other clinical trials
cobicistat
emtricitabine
tenofovir alafenamide
abnormal dreamscobicistat
elvitegravir
emtricitabine
tenofovir df
abnormal dreams
insomnia
suicidal ideation
suicide attemptelvitegravir
depressionemtricitabine
tenofovir df
depression
anxiety
clinical trials of cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
serum creatinine
second week of therapy
weeks
therapy-naive patients
change from baseline
mg/dl
mcmol/l
weeks of therapy
increases from baseline
cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide than increases with cobicistat
elvitegravir
emtricitabine
tenofovir df at weeks
trial in hiv
infected patients with egfr
ml/min
renal dysfunction
patients with egfr
ml/min
cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
transient acute renal failure
patient with egfr over ml/min
trials in therapy-naive hiv
infected patients
median egfr ml/min at baseline
serum creatinine
mg/dl from baseline
week with cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
cobicistat
elvitegravir
emtricitabine
tenofovir df
median upcr
mg/g at baseline
week with cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
mg/g
mg/g at baseline
week
cobicistat
elvitegravir
emtricitabine
tenofovir df
trial in virologically-suppressed tenofovir
df-treated patients
egfr ml/min at baseline
cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
initial regimen
serum creatinine
baseline for both
median upcr
mg/g at baseline
mg/g at week in those
cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
mg/g at baseline
mg/g at week in those
initial regimen
trial in renal dysfunction patients
baseline egfr
ml/min
using cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
serum creatinine
mg/dl at baseline
week
median upcr
mg/g at baseline
mg/g at week
elevated serum creatinine
grades
patients
using cobicistat
elvitegravir
emtricitabine
tenofovir df
clinical trials
estimated crcl
cobicistat
elvitegravir
emtricitabine
tenofovir df therapy
change in egfr
ml/min after weeks of therapy
clinical trial in hiv
infected therapy-naive patients with mild
moderate renal dysfunction
egfr
ml/min
change in serum creatinine
egfr
mg/dl
ml/min
cobicistat
elvitegravir
emtricitabine
tenofovir df
acute tubular necrosis
nephritis
including
acute interstitial nephritis
nephrogenic diabetes insipidus
clinical trials
postmarketing experience for tenofovir df with other antiretrovirals
acute tubular necrosis
nephrogenic diabetes insipidus
postmarketing experience with tenofovir df
proximal renal tubulopathy
tenofovir df
crcl
patients
stopping
drug
rhabdomyolysis
osteomalacia
bone abnormalities
contributing
fractures
hypokalemia
muscular weakness
myopathy
hypophosphatemia
result of proximal renal tubulopathy
cobicistat
emtricitabine
tenofovir alafenamide
frequency
increased serum creatinine
worsening
worsening renal dysfunction
transient acute renal failure
urine
protein-to-creatinine ratio
upcr
worsening
worsening renal functioncobicistat
elvitegravir
emtricitabine
tenofovir df
elevated serum creatinine-uncommon
renal failure
proximal renal tubulopathy
fanconi syndrome acquired-frequency
new onset
worsening
worsening renal impairment
including
acute renal failure
fanconi syndrome
laboratory findings
proximal renal tubular dysfunction
estimated crcl
estimated glomerular filtration rate
egfr
upcrcobicistat
frequency
increased serum creatinine
estimated crcl
tubular secretion of creatinine
renal glomerular function
tenofovir df
acute tubular necrosis
nephritis
including
acute interstitial nephritis
nephrogenic diabetes insipidus-postmarketing reports
renal insufficiency
acute renal failure
renal failure
fanconi syndrome
proximal renal tubulopathy
creatinine
interstitial nephritis
including
acute cases
vesiculobullous rash
pustular rash
maculopapular rash
pruritus
urticaria
skin discoloration
increased pigmentation
angioedema
clinical trials
postmarketing experience for tenofovir df with other antiretrovirals
cobicistat
emtricitabine
tenofovir alafenamide
rash-uncommon
prurituscobicistat
elvitegravir
emtricitabine
tenofovir df
rash
rash event
dermatitis
drug eruption
eczema
pruritus
generalized pruritus
rash
erythematous rash
generalized rash
macular rash
maculopapular rash
morbilliform rash
papular rash
pruritic rash
urticaria
emtricitabine
frequency
skin discoloration
palmar-plantar hyperpigmentation
postmarketing reports
angioedema
tenofovir df
vesiculobullous rash
pustular rash
maculopapular rash
pruritus
urticaria
skin discoloration
increased pigmentation
angioedema-postmarketing reports
rash
elevated ast
uln
patients
using cobicistat
elvitegravir
emtricitabine
tenofovir alafenamide
cobicistat
elvitegravir
emtricitabine
tenofovir df
elevated alt
uln
patients
using cobicistat
elvitegravir
emtricitabine
tenofovir df
severe acute exacerbations of hepatitis b
patients
hbv
hiv
discontinuation of emtricitabine
tenofovir df
liver failure
liver decompensation in some emtricitabine-treated patients
elevated alt
units/l in males
units/l in females
elevated bilirubin
uln
patients
receiving emtricitabine
tenofovir df with other antiretroviral drugs in other clinical trials
increased transaminases
hyperbilirubinemia
hepatic steatosis
hepatitis
clinical trials
postmarketing experience for tenofovir df with other antiretrovirals
hepatic steatosis
hepatitis
postmarketing experience with tenofovir df
lactic acidosis
steatosis
including
fatal cases
use of nucleoside analogs
cobicistat
emtricitabine
tenofovir alafenamide
elevated astcobicistat
elvitegravir
emtricitabine
tenofovir df
elevated ast
elevated altemtricitabine
frequency
liver failure
liver decompensationemtricitabine
tenofovir df
frequency
severe acute exacerbations of hepatitis b
elevated alt
elevated bilirubintenofovir df
increased transaminases
hyperbilirubinemia-rare
hepatic steatosis
hepatitis-frequency
lactic acidosis/severe hepatomegaly with steatosis-postmarketing reports
increased liver enzymes
ast
alt
ggt
cobicistat
emtricitabine
tenofovir df
upper
respiratory tract infection
bronchitisemtricitabine
tenofovir df
nasopharyngitis
pneumonia
sinusitis
upper respiratory tract infection
cough
rhinitistenofovir df
postmarketing reports
dyspnea
nasopharyngitis
pneumonia
sinusitis
upper respiratory tract infection
cough
rhinitis
patients
receiving emtricitabine
tenofovir df with other antiretroviral drugs in other clinical trials
cobicistat
emtricitabine
tenofovir df
ocular icterus
cobicistat
emtricitabine
tenofovir df
frequency
immune reconstitution/reactivation syndrome
autoimmune disorders in the setting of immune reconstitution
graves
disease
polymyositis
guillain-barre syndrome
emtricitabine
postmarketing reports
immune reconstitution syndrometenofovir df
postmarketing reports
immune reconstitution syndrome
emtricitabine
tenofovir df
frequency
decreased neutrophilsemtricitabine
anemiatenofovir df
neutropenia-uncommon
anemia
decreased neutrophils
mm
patients
receiving emtricitabine
tenofovir df with other antiretroviral drugs in other clinical trials
anemia
clinical trials
postmarketing experience for emtricitabine with other antiretrovirals
neutropenia
anemia
clinical trials
postmarketing experience for tenofovir df with other antiretrovirals
allergic reaction
clinical trials
postmarketing experience for tenofovir df with other antiretrovirals
allergic reaction
including angioedema
postmarketing experience with tenofovir df
tenofovir df
allergic reaction
tenofovir df
frequency
higher serum
parathyroid hormone levels
side effects of stribild
fda
healthcare professional for medical advice
cloudy urine
stomach discomfort
pain
bloody urine
bone fractures
bone pain
change in urination
convulsions
cough
dark-colored urine
decreased appetite
difficulty with swallowing
dizziness
dry mouth
irregular heartbeat
fast, shallow breathing
fever
general feeling of discomfort
increased thirst
hive-like swelling on the face
eyelids
lips
tongue
throat
hands
legs
feet
sex organs
light-colored stools
side pain
mood changes
muscle pain
cramps
stiffness
nausea
vomiting
diarrhea
numbness
tingling in the hands
feet
lips
puffiness
swelling of the eyelids
eyes
face
lips
tongue
skin rash
hives
itching
sleepiness
swelling of the face
fingers
lower legs
tightness in the chest
trouble breathing
unusual tiredness
weakness
weight gain
yellow eyes
skin
abnormal dreams
headache
bloated
full feeling
passing gas
trouble sleeping
unusual drowsiness
chills
constipation
indigestion
lack
loss of strength
pains in the stomach
side
abdomen
radiating
back